Anavex Life Sciences Corp (AVXL)

[XenaLives]

Notable posts - 10/17/18


Australian press covering the 2-73 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143772297
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143773822
Apologies and thanks to the poster who first posted this article, having trouble keeping up with the good news:
https://www.yourlifechoices.com.au/health/news/alzheimers-trial-delivers-results

UK press covering the 2-73 trial (repeat of AU coverage):
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143772909
_________________________________________________________________________________________


Hampel SPEAKS!....
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142864055

Slides:
https://www.anavex.com/wp-content/uploads/2018/07/Anavex-AAIC-2018-DT-01-Presentation.pdf
_________________________________________________________________________________________

Hampel SPEAKS AGAIN!.... at the VI International Congress on Research and Innovation in Neurodegenerative Diseases:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143924640

Comments on the above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143921147

_________________________________________________________________________________________

Hampel will speak yet AGAIN!

CTAD Late Breaker Oral Communications Update!

10/26, 3:30-3:45pm - Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers

Harald Hampel, MD, PhD1, Mohammad Afshar, MD, PhD2, Frédéric Parmentier, PhD2, Coralie Williams, MSc2, Adrien Etcheto, MSc2, Federico Goodsaid, PhD3, Christopher U Missling, PhD4; 1Department of Neurology, Sorbonne University, Paris, France, 2Ariana Pharma, Paris, France, 3Regulatory Pathfinders LLC, San Francisco, CA, 4Anavex Life Sciences Corp., New York, NY

http://www.ctad-alzheimer.com/files/files/Late%20call%20for%20abstracts.docx.pdf

Thanks to TTTav66 for the above post.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143655755

Information on Federico Goodsaid, Regulatory Pathfinders - co-presenter with Hampel:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143696879
https://www.linkedin.com/in/regulatory
pathfinders (Thanks blanka)

_________________________________________________________________________________________

Dec. 11 NYAS symposium, Alzheimer’s Disease Therapeutics: Alternatives to Amyloid, Nell Rebowe with Dr. Rudy Tanzi and Dr. Howard Fillit of the Alzheimers's Drug Discovery Foundation

_https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143979620
________________________________________________________________________________________


Anavex SAB member Dr Paul Aisen speaks about PET Scans:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143921781
_________________________________________________________________________________________

Dr Robert Lisak’s MS poster presented at the 2018 ECTRIMS conference:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144223191&txt2find=ectrims
_________________________________________________________________________________________


An excellent summary of why we are here from poster sokol:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143320176

CRISPER discover of likely MOA for 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144274561

From dadofmarcmax, the linked site has TONS of info:
"Why does Anavex 2-73 have effects on seemingly different neurodegenerative disorders? What makes it so special? "
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143816865

Missling has a strategy - one poster's read of that strategy:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144051610

Charts showing periods of institutional accumulation:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144037184

Basic biology concepts for Alzheimer’s disease
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137348423

Alzheimer's and Sleep:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134772774
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134771894

Dangerous medicines and mitochondrial dysfunction:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142393634&txt2find=mitochondrial

Shareholder meeting report:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140128467&txt2find=shareholder|meeting

What is a Special Protocol Assessment?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140087471

Precision Medicine and “The Economics of Drug Development”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144010889

Arguments for accelerated approval for 2-73.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143620275
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143624077

Missling states that PET scans will be used in P2/3 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143981335

How the Parkinson's Dementia trial may help expedite Alzheimer's approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143580569

Perspective on how quickly Anavex could morph into a profitable entity , making further dilution unnecessary. This may provide urgency for institutions to establish a position where stock has limited liquidity resulting in a pre-approval ramp up of pricing.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143560772

AVXL 2-73 and cerebral blood flow:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143582952

Anavex and Ariana (thanks TTAV66)
"Ariana Pharma promoting their work with Anavex. Nice write up, including the further reading section where they point to the upcoming CTAD presentation and detail their full history of collaboration with Anavex. "
http://www.arianapharma.com/2018/09/alzheimer-precision-medicine/

Of Mice and Men - Alzheimer's drug development through the years:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143978495

Brain cells from stem cells at Lund University:
https://www.lunduniversity.lu.se/article/new-method-grows-brain-cells-from-stem-cells-quickly-and-efficiently

Dr. Tangui Maurice on the Sigma 1 - 2015 video:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143980208

Dr. Tanzi on infection and Alzheimer's, also "soda brain".
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143979877

Did BIIB blink?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143525102

Anavex - Biogen & MS
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143729928
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143732818
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143734046
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144040837